Lactate dehydrogenase B is required for the growth of KRAS-dependent lung adenocarcinomas

Clinical Cancer Research

Volumn 19, Issue 4, 2013, Pages 773-784

  McCleland, Mark L ^a   Adler, Adam S ^a   Deming, Laura ^a   Cosino, Ely ^a   Lee, Leslie ^a   Blackwood, Elizabeth M ^a   Solon, Margaret ^a   Tao, Janet ^a   Li, Li ^a   Shames, David ^a   Jackson, Erica ^a   Forrest, William F ^a   Firestein, Ron ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

K RAS PROTEIN; LACTATE DEHYDROGENASE; LACTATE DEHYDROGENASE ISOENZYME 1; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

AMPLICON; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE DOSAGE; GENE IDENTIFICATION; GENE MUTATION; GENE SILENCING; GLYCOLYSIS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; MICROARRAY ANALYSIS; ONCOGENE K RAS; PREDICTION; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; RNA INTERFERENCE; TUMOR XENOGRAFT; UPREGULATION; WILD TYPE;

ADENOCARCINOMA; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; ISOENZYMES; KAPLAN-MEIER ESTIMATE; L-LACTATE DEHYDROGENASE; LUNG NEOPLASMS; MICE; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RNA, SMALL INTERFERING; TRANSPLANTATION, HETEROLOGOUS;

EID: 84874025568     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2638     Document Type: Article

References (48)

1. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008;359:1367-80.
2. Singh M, Lima A, Molina R, Hamilton P, Clermont AC, Devasthali V, et al. Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol 2010;28: 585-93.
3. Camidge DR, Doebele RC. Treating ALK-positive lung cancer-early successes and future challenges. Nat Rev Clin Oncol 2012;9:268-277.
4. Carter CA, Giaccone G. Treatment of nonsmall cell lung cancer: overcoming the resistance to epidermal growth factor receptor inhibitors. Curr Opin Oncol 2012;24:123-9.
5. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
6. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
7. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.N Engl J Med 2010;363:1693-703.
8. Riely GJ, Kris MG, Rosenbaum D, Marks J, Li A, Chitale DA, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 2008;14: 5731-4.
9. Sasaki H, Hikosaka Y, Kawano O, Moriyama S, Yano M, Fujii Y. Evaluation of Kras gene mutation and copy number gain in non-small cell lung cancer. J Thorac Oncol 2011;6:15-20.
10. Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007;450:893-8.
11. Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 2008;9:517-31.
12. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003;3:11-22.
13. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009;462:108-12.
14. Dolma S, Lessnick SL, Hahn WC, Stockwell BR. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell 2003;3: 285-96.
15. Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF, et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009;137:835-48.
16. Torrance CJ, Agrawal V, Vogelstein B, Kinzler KW. Use of isogenic human cancer cells for high-throughput screening and drug discovery. Nat Biotechnol 2001;19:940-5.
17. Gray DC, Hoeflich KP, Peng L, Gu Z, Gogineni A, Murray LJ, et al. pHUSH: a single vector system for conditional gene expression. BMC Biotechnol 2007;7:61.
18. Adler AS, McCleland ML, Truong T, Lau S, Modrusan Z, Soukup TM, et al.CDK8maintains tumor de-differentiation and embryonic stem cell pluripotency. Cancer Res 2012;72:2129-39.
19. Okayama H, Kohno T, Ishii Y, Shimada Y, Shiraishi K, Iwakawa R, et al. Identification of genes upregulated in ALK-positive and EGFR/ KRAS/ALK-negative lung adenocarcinomas. Cancer Res 2012;72: 100-11.
20. Hoeflich KP, O'Brien C, Boyd Z, Cavet G, Guerrero S, Jung K, et al. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 2009;15:4649-64.
21. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003;34:267-73.
22. Takeuchi T, Tomida S, Yatabe Y, Kosaka T, Osada H, Yanagisawa K, et al. Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol 2006;24:1679-88.
23. Taatjes DJ. The human mediator complex: a versatile, genome-wide regulator of transcription. Trends Biochem Sci 2010;35:315-22.
24. Bayley JP, Devilee P. The Warburg effect in 2012. Curr Opin Oncol 2012;24:62-7.
25. Porporato PE, Dhup S, Dadhich RK, Copetti T, Sonveaux P. Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front Pharmacol 2011;2:49.
26. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004;10:789-99.
27. Singh A, Greninger P, Rhodes D, Koopman L, Violette S, Bardeesy N, et al. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell 2009;15:489-500.
28. Warburg O. On the origin of cancer cells. Science 1956;123:309-14.
29. Halestrap AP. The monocarboxylate transporter family - structure and functional characterization. IUBMB Life 2012;64:1-9.
30. Pinheiro C, Longatto-Filho A, Azevedo-Silva J, Casal M, Schmitt FC, Baltazar F. Role of monocarboxylate transporters in human cancers: state of the art. J Bioenerg Biomembr 2012;44:127-39.
31. Levine AJ, Puzio-Kuter AM. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 2010;330:1340-4.
32. Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB. Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev 2008;18: 54-61.
33. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 2009;458:762-5.
34. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A 2008;105:18782-7.
35. Chiaradonna F, Gaglio D, Vanoni M, Alberghina L. Expression of transforming K-Ras oncogene affects mitochondrial function and morphology in mouse fibroblasts. Biochim Biophys Acta 2006;1757: 1338-56.
36. Chiaradonna F, Sacco E, Manzoni R, Giorgio M, Vanoni M, Alberghina L. Ras-dependent carbon metabolism and transformation in mouse fibroblasts. Oncogene 2006;25:5391-404.
37. Gaglio D, Metallo CM, Gameiro PA, Hiller K, Danna LS, Balestrieri C, et al. Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth. Mol Syst Biol 2011;7:523.
38. Vizan P, Boros LG, Figueras A, Capella G, Mangues R, Bassilian S, et al. K-ras codon-specific mutations produce distinctive metabolic phenotypes in NIH3T3 mice [corrected] fibroblasts. Cancer Res 2005;65:5512-5.
39. Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sananikone E, et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 2012;149:656-70.
40. Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 2006;9:425-34.
41. Leiblich A, Cross SS, Catto JW, Phillips JT, Leung HY, Hamdy FC, et al. Lactate dehydrogenase-B is silenced by promoter hypermethylation in human prostate cancer. Oncogene 2006;25:2953-60.
42. Liao AC, Li CF, Shen KH, Chien LH, Huang HY, Wu TF. Loss of lactate dehydrogenase B subunit expression is correlated with tumour progression and independently predicts inferior disease-specific survival in urinary bladder urothelial carcinoma. Pathology 2011;43:707-12.
43. Thangaraju M, Carswell KN, Prasad PD, Ganapathy V. Colon cancer cells maintain low levels of pyruvate to avoid cell death caused by inhibition of HDAC1/HDAC3. Biochem J 2009;417:379-89.
44. Zha X, Wang F, Wang Y, He S, Jing Y, Wu X, et al. Lactate dehydrogenase B is critical for hyperactive mTOR-mediated tumorigenesis. Cancer Res 2011;71:13-8.
45. Dawson DM, Goodfriend TL, Kaplan NO. Lactic dehydrogenases: functions of the two types rates of synthesis of the two major forms can be correlated with metabolic differentiation. Science 1964;143: 929-33.
46. Markert CL, Shaklee JB, Whitt GS. Evolution of a gene. Multiple genes for LDH isozymes provide a model of the evolution of gene structure, function and regulation. Science 1975;189:102-14.
47. Kanno T, Sudo K, Takeuchi I, Kanda S, Honda N, Nishimura Y, et al. Hereditary deficiency of lactate dehydrogenase M-subunit. Clin Chim Acta 1980;108:267-76.
48. Joukyuu R, Mizuno S, Amakawa T, Tsukada T, Nishina T, Kitamura M. Hereditary complete deficiency of lactate dehydrogenase H-subunit. Clin Chem 1989;35:687-90.